Gilead did not violate patents on HIV prevention drug: Jury

Delaware jury acquits Tuesday Gilead Sciences The US government accused it of infringing a patent on an HIV prevention drug held by the Centers for Disease and Prevention.

The U.S. government sued Gilead in 2019, alleging that the company profited from CDC patents by selling oral drugs Truvada and Descovy to prevent HIV infection.

But a jury found the government’s patent claim on an HIV prevention regimen called pre-exposure prophylaxis, or PrEP, invalid after a multiday trial in federal court.

“Today’s decision affirms our longstanding belief that we have always had the right to make Truvada and Descovy for PrEP available to everyone who needs it,” Deb Telman, Gilead’s general counsel, said in a statement Tuesday.

“Gilead will continue to support collaborations, including our more than 15-year efforts with the U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC), as we work together to achieve our shared goal of providing universal access to individuals to end the HIV epidemic,” Terman said.

This is breaking news. Check for updates.